Stockreport

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study [Yahoo! Finance]

Vaxcyte, Inc.  (PCVX) 
PDF -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster D [Read more]